D. Gschwantler-Kaulich

发表

Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.

V. Pankratz, F. Couch, B. Ponder, 2010, Human molecular genetics.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS genetics.

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

Mads Thomassen, Etienne Rouleau, Dieter Niederacher, 2010, Cancer research.

Cadherin-11 expression is upregulated in invasive human breast cancer

C. Singer, D. Gschwantler-Kaulich, Y. Tan, 2016, Oncology letters.

Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2006, European journal of cancer.

Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro

C. Singer, D. Gschwantler-Kaulich, J. Gamper, 2017, PloS one.

Selective spatial upregulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism.

T. Thalhammer, E. Kubista, C. Singer, 2006, Endocrine-related cancer.

Beta-hCG/LH receptor (b-HCG/LH-R) expression is increased in invasive versus preinvasive breast cancer: implications for breast carcinogenesis?

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2009, Journal of Cancer Research and Clinical Oncology.

Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations

C. Singer, D. Gschwantler-Kaulich, M. Hengstschläger, 2013, Journal of Cancer Research and Clinical Oncology.

Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria

C. Singer, D. Gschwantler-Kaulich, S. Narod, 2014, Clinical genetics.

Mesh versus acellular dermal matrix in immediate implant-based breast reconstruction - A prospective randomized trial.

C. Singer, D. Gschwantler-Kaulich, A. Fink-Retter, 2016, European Journal of Surgical Oncology.

Efficacy of Primary Systemic Chemotherapy Regimen Containing Anthracyclines with/without Taxanes in Comparison to CMF in Women with Early Breast Cancer

E. Kubista, D. Gschwantler-Kaulich, T. Bachrich, 2007, Journal of chemotherapy.

Increase in ezrin expression from benign to malignant breast tumours

S. Steurer, M. Salama, C. Singer, 2013, Cellular Oncology.

Differential gene expression profile in breast cancer-derived stromal fibroblasts

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2007, Breast Cancer Research and Treatment.

Human papillomavirus DNA integration and messenger RNA transcription in cervical low- and high-risk squamous intraepithelial lesions in Austrian women

D. Gschwantler-Kaulich, A. Fink-Retter, G. Hudelist, 2007, International Journal of Gynecologic Cancer.

Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.

J. Attems, E. Kubista, C. Singer, 2007, Endocrine-related cancer.

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers

R. Zeillinger, C. Singer, D. Gschwantler-Kaulich, 2017, PloS one.

Her‐2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab‐based therapy in patients with metastatic breast cancer

J. Attems, E. Kubista, C. Singer, 2006, International journal of cancer.

Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2011, Tumor Biology.

Differential spatial expression and activation pattern of EGFR and HER-2 in human breast cancer.

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors influencing the identification rate of the sentinel node in breast cancer.

E. Kubista, M. Seifert, C. Singer, 2011, European journal of cancer care.

Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients

C. Singer, D. Gschwantler-Kaulich, S. Polterauer, 2019, Cancer medicine.

Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2007, Journal of Cancer Research and Clinical Oncology.

Expression of Aromatase and Estrogen Sulfotransferase in Eutopic and Ectopic Endometrium: Evidence for Unbalanced Estradiol Production in Endometriosis

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2007, Reproductive Sciences.

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

D. Steinemann, F. Couch, B. Bonanni, 2020, Genetics in Medicine.

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

Michael Jones, Peter Kraft, Arnaud Droit, 2017, Nature Genetics.

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

Mads Thomassen, Stephen Fox, Dieter Niederacher, 2011, Breast Cancer Research.

PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer

J. Attems, M. Salama, C. Singer, 2017, PloS one.

Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers

Peter Devilee, Alfons Meindl, Lesley McGuffog, 2010, Breast Cancer Research.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Mads Thomassen, Nina Ditsch, Dieter Niederacher, 2009, Human molecular genetics.

Increase in ezrin expression from benign to malignant breast tumours

S. Steurer, M. Salama, C. Singer, 2013, Cellular Oncology.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS Genetics.

Altered Expression of RB and pRB in Tissue Arrays of Primary Breast Cancers and Matched Axillary Lymph Node Metastases

C. Singer, D. Gschwantler-Kaulich, A. Reiner, 2022, The breast journal.

HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK

H. Kölbl, C. Singer, D. Gschwantler-Kaulich, 2016, PloS one.

Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers

M. Salama, C. Singer, D. Gschwantler-Kaulich, 2015, Molecular genetics & genomic medicine.

Complication rates among women undergoing preventive mastectomy: An Austrian registry

G. Dorffner, C. Singer, D. Gschwantler-Kaulich, 2020, The breast journal.

Direct‐to‐implant breast reconstruction: Higher complication rate vs cosmetic benefits

C. Singer, D. Gschwantler-Kaulich, M. Salama, 2018, The breast journal.

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)

G Rennert, N Weerasooriya, K Offit, 2009, British Journal of Cancer.

HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2009, Journal of Cancer Research and Clinical Oncology.

Incomplete surgical resection of DCIS results in activation of HER-2 in residual breast cancer cells.

M. Gnant, E. Kubista, C. Singer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells.

M. Gnant, E. Kubista, C. Singer, 2008, Endocrine-related cancer.

Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria

Z. Bago-Horvath, M. Seifert, C. Singer, 2022, BMC Cancer.

No evidence that GATA3 rs570613 SNP modifies breast cancer risk

K. Czene, P. Hall, V. Pankratz, 2009, Breast Cancer Research and Treatment.

Liver function indicators in patients with breast cancer before and after detection of hepatic metastases-a retrospective study

D. Gschwantler-Kaulich, I. Holzer, M. Marhold, 2023, PloS one.

Evidence for SMAD 3 as a modifier of breast cancer risk in BRCA 2 mutation carriers

V. Pankratz, F. Couch, T. Rebbeck, 2010 .

Combined Hysterectomy/Salpingo-oophorectomy and Mastectomy for Female-to-Male Transgender Persons: A Retrospective Update

D. Gschwantler-Kaulich, U. Kaufmann, R. Wenzl, 2019 .

Corrigendum to "Mesh versus acellular dermal matrix in immediate implant-based breast reconstruction - A prospective randomized trial" [Eur J Surg Oncol 42 (5) (2016) 665-671].

C. Singer, D. Gschwantler-Kaulich, A. Fink-Retter, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Interleukin-1alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity.

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Patient satisfaction after breast cancer surgery

R. Zeillinger, F. Fitzal, C. Singer, 2020, Wiener klinische Wochenschrift.

Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer"

T. Helbich, C. Singer, D. Gschwantler-Kaulich, 2023, BMC Cancer.

EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR.

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2005, Oncology reports.

CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study

D. Gschwantler-Kaulich, C. Singer, P. Gebhart, 2023, BMC Cancer.

Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer.

E. Kubista, C. Singer, D. Gschwantler-Kaulich, 2007, Oncology reports.

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

V. Pankratz, F. Couch, O. Olopade, 2010, Cancer research.

Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers

F. Couch, O. Olopade, T. Rebbeck, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Null Results in Brief Common Genetic Variation at BARD 1 Is Not Associated with Breast Cancer Risk in BRCA 1 or BRCA 2 Mutation Carriers

O. Olopade, T. Rebbeck, R. Eeles, 2011 .

Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.

F. Couch, B. Bonanni, J. Benítez, 2009, Human molecular genetics.